Anti-CCR8 antibodies and uses thereof - Vaccinex cancer treatment patents
Summary
Vaccinex, Inc. filed patent application US20260091108A1 covering anti-CCR8 antibodies and methods of treating cancer using those antibodies. The application, published April 2, 2026 with filing date November 19, 2025, names 11 inventors including Pamela M. Holland. CPC classifications indicate therapeutic antibody applications in oncology.
What changed
Vaccinex, Inc. filed patent application US20260091108A1 directed to antibodies or antigen-binding portions that specifically bind human CCR8, along with polynucleotides, vectors, and pharmaceutical compositions for treating diseases including cancer. The application discloses methods of administering anti-CCR8 antibodies to subjects in need thereof. Application number is 19394184.
This publication represents a patent application draft stage - no regulatory obligations are imposed on any party. Pharmaceutical companies, biotechnology firms, and researchers developing immunotherapy treatments should review the disclosed claims to assess potential freedom-to-operate implications for their own CCR8-targeted programs. No compliance deadlines or penalties apply.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-CCR8 ANTIBODIES AND USES THEREOF
Application US20260091108A1 Kind: A1 Apr 02, 2026
Assignee
Vaccinex, Inc.
Inventors
Pamela M. HOLLAND, Andrew LAKE, Austin DULAK, Ernest Smith, Maria Scrivens, Caroline Harvey, Renee Kirk, Leslie Balch, Sonia DAS, Christopher Converse Wells
Abstract
The present disclosure is directed to antibodies or antigen-binding portions thereof that specifically bind human CCR8, polynucleotides and vectors encoding the same, and pharmaceutical compositions comprising the same. Some aspects of the disclosure are directed to methods of treating a disease or condition comprising administering the anti-CCR8 antibody to a subject in need thereof.
CPC Classifications
A61K 39/39541 A61K 47/6849 A61P 35/00 C07K 16/2866 C07K 2317/31 C07K 2317/41 C07K 2317/622 C07K 2317/732 C07K 2317/92
Filing Date
2025-11-19
Application No.
19394184
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.